HUMALOG MIX 50/50
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 (HUMALOG MIX 50/50).
Insulin analog that binds to insulin receptors, activating downstream signaling pathways to promote glucose uptake, glycogen synthesis, and lipogenesis, and inhibit gluconeogenesis and ketogenesis.
| Metabolism | Hepatic metabolism via insulin-degrading enzyme (IDE) and nonspecific proteases. |
| Excretion | Primarily via renal excretion of insulin degradation products; less than 1% excreted as unchanged insulin. No significant biliary or fecal elimination. |
| Half-life | Subcutaneous injection: terminal half-life approximately 1-2 hours, reflecting clearance from the injection site and systemic elimination. Clinical context: allows twice-daily dosing. |
| Protein binding | Approximately 20-30% bound to plasma proteins, primarily albumin and immunoglobulins. Binding is not clinically significant for insulin action. |
| Volume of Distribution | Volume of distribution (Vd) for insulin lispro is approximately 0.26-0.34 L/kg, indicating distribution primarily into extracellular fluid and limited tissue binding. |
| Bioavailability | Subcutaneous injection: bioavailability is approximately 55-77% relative to intravenous administration, due to degradation at the injection site. |
| Onset of Action | Subcutaneous injection: onset of glucose-lowering effect occurs within 15-30 minutes due to the rapid-acting insulin lispro component (50% lispro). |
| Duration of Action | Subcutaneous injection: duration of action is up to 24 hours (median 18-24 hours), with a biphasic profile due to the combination of rapid-acting (lispro) and intermediate-acting (lispro protamine) components. Clinical note: twice-daily dosing typically provides basal and prandial coverage. |
Subcutaneous injection of 0.2 to 0.6 units/kg/day divided into 3 or more doses, with the preprandial dose based on blood glucose monitoring. Typical total daily dose is 0.5 units/kg/day. Administer within 15 minutes before or after a meal.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment for mild to moderate impairment; risk of hypoglycemia may increase. For GFR <30 mL/min, consider initiating at lower doses (e.g., 0.25 units/kg/day) with close monitoring. |
| Liver impairment | Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 20-30% and monitor hypoglycemia. Child-Pugh C: Dose reduction of 50% or more may be necessary; individualize based on glucose response. |
| Pediatric use | Initiate at 0.25-0.5 units/kg/day subcutaneously divided into multiple daily doses; titrate based on glycemic targets. For children aged 3-11 years, typical total daily dose 0.5-1.0 units/kg/day; for adolescents, 0.5-1.2 units/kg/day. |
| Geriatric use | Start at lower doses (e.g., 0.2-0.4 units/kg/day) to minimize hypoglycemia risk. Conservative titration advised, with emphasis on postprandial glucose monitoring. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMALOG MIX 50/50 (HUMALOG MIX 50/50).
| Breastfeeding | Insulin lispro is excreted in human milk in negligible amounts. No adverse effects on the nursing infant are expected. M/P ratio not clinically significant. Compatible with breastfeeding; may require adjustment of maternal insulin dose due to changes in insulin sensitivity postpartum. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. Fetal risks are primarily related to maternal glycemic control. Poor glycemic control in the first trimester increases risk of congenital anomalies; in the second and third trimesters, macrosomia, neonatal hypoglycemia, and respiratory distress syndrome. No known teratogenicity from insulin lispro itself. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to insulin lispro or any excipients","During episodes of hypoglycemia"]
| Precautions | ["Hypoglycemia is the most common adverse effect and can be life-threatening","Do not mix with other insulins; suspension must be resuspended before use","Changes in insulin strength, manufacturer, type, or method of administration may require dosage adjustment","Use with caution in patients with renal or hepatic impairment","May cause hypokalemia","Not for IV or IM use; only for subcutaneous injection"] |
Loading safety data…
| Fetal Monitoring | Monitor blood glucose and HbA1c frequently. Assess fetal growth via ultrasound. Monitor for maternal hypoglycemia, especially in first trimester. Ketonuria monitoring during illness or hyperglycemia. Standard prenatal care including fetal movement counts and non-stress tests in third trimester if indicated. |
| Fertility Effects | No known adverse effects on fertility. Poor glycemic control may contribute to menstrual irregularities and ovulatory dysfunction, which can be reversed with improved control. |